Genentech, Inc.

Raven Biotechnologies, Inc.

Macrogenics, Inc.

Genetech, Inc.

Macrogenics West, Inc.

Biomosaic Systems, Inc.

Ronghao Li

Jennie Powell Mather

Jian Chen

Penelope E Roberts

Zhuangyu Pan

Paul J Godowski

Melanie Rose Mark

R Glenn Hammonds, Jr

Tony Liang

Laura Bald

The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.

B7-H3L cell surface antigen and antibodies that bind thereto

The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.

Transferrin receptor antibodies

The present invention provides a method for generating human monoclonal antibodies, especially those that are specific for surface antigens representative of a particular cell type. The present invention also includes populations of monoclonal antibodies produced by the invention methods, populations of polynucleotides comprising sequences encoding the immunoglobulins or fragments thereof, which are capable of binding to antigens representative of a cell type of interest.

Methods and compositions for generating human monoclonal antibodies

This invention discloses a substantially pure population of human urinary bladder-derived epithelial cells and methods of isolating and culturing the urinary bladder-derived epithelial cells. In addition, several uses of human urinary bladder-derived epithelial cells and cells differentiating therefrom are disclosed herein.

Human fetal bladder-derived epithelial cells

RAAG10 cell surface target and a family of antibodies recognizing that target

Provided herein is disclosure about the identification and characterization of disease and cancer associated antigen PIPA. The invention also provides a family of monoclonal antibodies that bind to antigen PIPA, and methods of diagnosing and treating various human cancers and diseases that express PIPA.

Antigen PIPA and antibodies that bind thereto

The present invention provides cell arrays comprising a plurality of tubes containing populations of cells that are immobilized therein. The arrays are particularly useful for conducting comparative cell-based analyses. Specifically, the subject arrays allow protein-protein interactions to be studied in multiple types of cell simultaneously. The arrays also support simultaneous detection of the differential expression of a target polynucleotide in a multiplicity of cell types derived from multiple subjects. The subject arrays further permit high throughput screening for candidate modulators of a signal transduction pathway of interest. Further provided by the invention are kits, computer-implemented methods and systems for conducting the comparative cell-based analyses.

Cell arrays and the uses thereof

The translation product of the growth arrest-specific gene 6 (gas6) has been identified as an activator of the Mer receptor protein tyrosine kinase. The invention accordingly provides methods of activating Mer receptor in cells expressing it by exposing them to exogenous gas6 polypeptides. Also provided are methods of enhancing the growth, differentiation, or survival of such cells using gas6 polypeptides.

Mer receptor activation by gas6

A method for enhancing the survival and/or proliferation of Schwann cells (especially human Schwann cells) in cell culture is disclosed which involves culturing the cells in serum free culture medium comprising gas6 and other mitogenic agents, such as heregulin and forskolin. The culturing step is generally preceded by a pre-incubation period wherein nerve tissue comprising the Schwann cells is cultured under appropriate conditions and for a period of time such that demyelination occurs. The isolated Schwann cells can be used as cellular prostheses to treat patients with nervous system injuries. The invention also provides a cell culture medium for culturing Schwann cells.

Method of treating a nervous system injury with cultured schwann cells

An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides a method of activating the Rse receptor by exposing a cell comprising the Rse receptor to exogenous gas6 polypeptide. Moreover, the present invention is directed to a method for enhancing the survival, proliferation or differentiation of a cell comprising a Rse receptor by exposing the cell to exogenous gas6 polypeptide. The types of cells which can be treated according to the method include glial cells such as Schwann cells.

Growing community of inventors

Millbrae, CA, United States of America

Ronghao Li